Amberen
TINA.org investigated the marketing for Amberen, a menopause supplement brand owned and marketed by Alliance Pharmaceuticals, and found that it is deceptively promoted as “clinically proven” to provide menopause and perimenopause relief and able to treat a variety of menopausal symptoms, in violation of a federal court order entered in a case filed by the FTC.
To see TINA.org’s evidence, click here.
Timeline
2024
October 1
TINA.org files a complaint with the FTC regarding widespread deceptive marketing for Amberen, which violates a May 2016 federal court order TINA.org sends a copy of the complaint letter to the FDA, as well as to Alliance Pharmaceuticals.
2023
April
The FTC sends a Notice of Penalty Offenses Concerning Substantiation of Product Claims to Alliance Pharmaceuticals, current owner of the Amberen brand.
2020
December 29
Alliance Pharmaceuticals announces acquisition of Biogix, Inc., formerly called Lunada Biomedical.
2016
May 25
A Stipulated Order is entered in federal district court that permanently prohibits Lunada Biomedical, Inc. and its “successors and assigns” from, among other things, labeling and advertising Amberen as able to relieve hot flashes, night sweats, mood swings, sleeplessness, anxiety, and several other symptoms of menopause without competent and reliable scientific evidence that substantiates the claims. The order also requires Lunada Biomedical to pay more than $40 million.
Evidence
Featured
The Menopause Deception Epidemic
How the supplement industry is taking advantage of women and what TINA.org is doing to fight it.
The Latest
TINA.org Files FTC & FDA Complaints Against Menopause Supplement Brands
An investigation into the menopause supplement industry by consumer advocacy organization truthinadvertising.org (TINA.org) has revealed a hotbed of deceptive advertising. The ad watchdog has amassed nearly 2,000 examples of problematic health…
Consumer Alert: Menopause Supplements
Proceed with caution when it comes to menopause marketing.